Form 4: Amicus Therapeutics Executive Acquires Shares and Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
David Michael Clark, Chief People Officer of Amicus Therapeutics, reports acquisition of shares related to performance stock units and disposition of shares to cover tax obligations.
Summary
- On February 11, 2025, David Michael Clark, Chief People Officer of Amicus Therapeutics, acquired 52,338 shares of common stock related to the achievement of 2022 Performance Stock Units (PRSUs) as determined by the Board of Directors.
- On the same day, Clark disposed of 20,593 shares of common stock at a price of $9.57 to cover tax obligations.
- Following these transactions, Clark directly owns 348,261 shares of Amicus Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects standard executive compensation transactions, with no indication of positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but it's primarily related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/11/2025 | Date of stock acquisition and disposition. |
| 02/13/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.